{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T16:48:19Z","timestamp":1792082899227,"version":"4.4.0"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81471218"],"award-info":[{"award-number":["81471218"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Natural Science Foundation of Guangdong Province, China","award":["2014A030313014"],"award-info":[{"award-number":["2014A030313014"]}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jni-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Neuroimmunology"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1016\/j.jneuroim.2018.05.014","type":"journal-article","created":{"date-parts":[[2018,5,28]],"date-time":"2018-05-28T12:40:30Z","timestamp":1527511230000},"page":"83-91","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":54,"special_numbering":"C","title":["Different features between pediatric-onset and adult-onset patients who are seropositive for MOG-IgG: A multicenter study in South China"],"prefix":"10.1016","volume":"321","author":[{"given":"Lu","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaonan","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaobo","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haixia","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaqing","family":"Shu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanyu","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueqiang","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengqi","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisheng","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.jneuroim.2018.05.014_bb0005","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1136\/jnnp-2014-309057","article-title":"Collateral benefit: the comeback of MOG antibodies as a biomarker in neurological practice","volume":"86","author":"Aktas","year":"2015","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"3","key":"10.1016\/j.jneuroim.2018.05.014_bb0010","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1136\/jnnp-2014-308346","article-title":"Clinical and neuroradiological differences of paediatric acute disseminating encephalomyelitis with and without antibodies to the myelin oligodendrocyte glycoprotein","volume":"86","author":"Baumann","year":"2015","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"2","key":"10.1016\/j.jneuroim.2018.05.014_bb0015","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1056\/NEJMoa022328","article-title":"Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event","volume":"349","author":"Berger","year":"2003","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.jneuroim.2018.05.014_bb0020","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1172\/JCI28334","article-title":"1Myelin oligodendrocyte glycoprotein-specific T and B cells cooperate to induce a Devic-like disease in mice","volume":"16","author":"Bettelli","year":"2006","journal-title":"J. Clin. Invest."},{"issue":"3","key":"10.1016\/j.jneuroim.2018.05.014_bb0025","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.clim.2010.11.013","article-title":"Temporal dynamics of anti-MOG antibodies in CNS demyelinating diseases","volume":"138","author":"Di Pauli","year":"2011","journal-title":"Clin. Immunol."},{"issue":"3","key":"10.1016\/j.jneuroim.2018.05.014_bb0030","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1212\/WNL.0000000000004117","article-title":"Diagnostic algorithm for relapsing acquired demyelinating syndromes in children","volume":"89","author":"Hacohen","year":"2017","journal-title":"Neurology"},{"issue":"9","key":"10.1016\/j.jneuroim.2018.05.014_bb0035","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1212\/WNL.0000000000004312","article-title":"Prognostic relevance of MOG antibodies in children with an acquired demyelinating syndrome","volume":"89","author":"Hennes","year":"2017","journal-title":"Neurology"},{"issue":"7","key":"10.1016\/j.jneuroim.2018.05.014_bb0040","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1177\/1352458514555785","article-title":"Antibodies to MOG and AQP4 in adults with neuromyelitis optica and suspected limited forms of the disease","volume":"21","author":"H\u00f6ftberger","year":"2015","journal-title":"Mult. Scler."},{"issue":"12","key":"10.1016\/j.jneuroim.2018.05.014_bb0045","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1177\/1352458514566666","article-title":"Anti-MOG antibodies plead against MS diagnosis in an Acquired Demyelinating Syndromes cohort","volume":"21","author":"Ketelslegers","year":"2015","journal-title":"Mult. Scler."},{"issue":"12","key":"10.1016\/j.jneuroim.2018.05.014_bb0050","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1212\/WNL.0b013e31826aac4e","article-title":"Myelin-oligodendrocyte glycoprote in antibodies in adults with a neuromyelitis optica phenotype","volume":"79","author":"Kitley","year":"2012","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.jneuroim.2018.05.014_bb0055","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1001\/jamaneurol.2013.5857","article-title":"Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: a comparative study","volume":"71","author":"Kitley","year":"2014","journal-title":"JAMA Neurol."},{"issue":"2","key":"10.1016\/j.jneuroim.2018.05.014_bb0060","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0149411","article-title":"B cell, Th17, and neutrophil related cerebrospinal fluid cytokine\/chemokines are elevated in MOG antibody associated demyelination","volume":"11","author":"Kothur","year":"2016","journal-title":"PLoS One"},{"issue":"9","key":"10.1016\/j.jneuroim.2018.05.014_bb0065","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1172\/JCI28330","article-title":"Spontaneous opticospinal encephalomyelitis in a double-transgenic mouse model of autoimmune T cell\/B cell cooperation","volume":"116","author":"Krishnamoorthy","year":"2006","journal-title":"J. Clin. Invest."},{"issue":"10","key":"10.1016\/j.jneuroim.2018.05.014_bb0070","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1177\/1352458513484547","article-title":"International Pediatric Multiple Sclerosis Study Group criteria for pediatric multiple sclerosis and immune-mediated central nervous system demyelinating disorders: revisions to the 2007 definitions","volume":"19","author":"Krupp","year":"2013","journal-title":"Mult. Scler."},{"key":"10.1016\/j.jneuroim.2018.05.014_bb0080","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1186\/1742-2094-8-184","article-title":"Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitis optica and related disorders","volume":"8","author":"Mader","year":"2011","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.jneuroim.2018.05.014_bb0085","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/B978-0-444-52910-7.00026-X","article-title":"Brain development and the immune system: an introduction to inflammatory and infectious diseases of the child's brain","volume":"112","author":"Marc","year":"2013","journal-title":"Handb. Clin. Neurol."},{"issue":"4","key":"10.1016\/j.jneuroim.2018.05.014_bb0090","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2015-007766","article-title":"Antibodies to myelin oligodendrocyte glycoprotein in idiopathic optic neuritis","volume":"5","author":"Nakajima","year":"2015","journal-title":"BMJ Open"},{"issue":"4","key":"10.1016\/j.jneuroim.2018.05.014_bb0095","doi-asserted-by":"crossref","first-page":"505","DOI":"10.4103\/0972-2327.192389","article-title":"Serological markers associated with neuromyelitis optica spectrum disorders in South India","volume":"19","author":"Pandit","year":"2016","journal-title":"Ann. Indian Acad. Neurol."},{"key":"10.1016\/j.jneuroim.2018.05.014_bb0100","doi-asserted-by":"crossref","first-page":"529","DOI":"10.3389\/fimmu.2017.00529","article-title":"Myelin oligodendrocyte glycoprotein: deciphering a target in inflammatory demyelinating diseases","volume":"8","author":"Peschl","year":"2017","journal-title":"Front. Immunol."},{"issue":"2","key":"10.1016\/j.jneuroim.2018.05.014_bb0105","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1002\/ana.22366","article-title":"Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria","volume":"69","author":"Polman","year":"2011","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.jneuroim.2018.05.014_bb0110","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s12974-015-0256-1","article-title":"Anti-MOG antibodies are present in a subgroup of patients with a neuromyelitis opticaphenotype","volume":"12","author":"Pr\u00f6bstel","year":"2015","journal-title":"J. Neuroinflammation"},{"issue":"4","key":"10.1016\/j.jneuroim.2018.05.014_bb0115","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000040","article-title":"Antibodies to myelin oligodendrocyte glycoprotein in bilateral and recurrent optic neuritis","volume":"1","author":"Ramanathan","year":"2014","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"4","key":"10.1016\/j.jneuroim.2018.05.014_bb0120","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.autrev.2015.12.004","article-title":"Anti-MOG antibody: the history, clinical phenotype, and pathogenicity of a serum biomarker for demyelination","volume":"15","author":"Ramanathan","year":"2016","journal-title":"Autoimmun. Rev."},{"issue":"1","key":"10.1016\/j.jneuroim.2018.05.014_bb0125","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000060","article-title":"MOG antibody-associated diseases","volume":"2","author":"Reindl","year":"2015","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"Suppl. 3","key":"10.1016\/j.jneuroim.2018.05.014_bb0130","first-page":"511","article-title":"Critical periods of vulnerability for the developing nervous system: evidence from humans and animal models","volume":"108","author":"Rice","year":"2000","journal-title":"Environ. Health Perspect."},{"issue":"Pt 10","key":"10.1016\/j.jneuroim.2018.05.014_bb0135","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1093\/brain\/awh260","article-title":"Clinicopathological study of a myelin oligodendrocyte glycoprotein-induced demyelinating disease in LEW.1AV1 rats","volume":"127","author":"Sakuma","year":"2004","journal-title":"Brain"},{"issue":"6","key":"10.1016\/j.jneuroim.2018.05.014_bb0140","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1212\/WNL.0000000000000101","article-title":"Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders","volume":"82","author":"Sato","year":"2014","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.jneuroim.2018.05.014_bb0145","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000225","article-title":"Neuromyelitis optica spectrum disorders: comparison according to the phenotype and serostatus","volume":"3","author":"Sep\u00falveda","year":"2016","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"4","key":"10.1016\/j.jneuroim.2018.05.014_bb0150","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s11065-010-9148-4","article-title":"The basics of brain development","volume":"20","author":"Stiles","year":"2010","journal-title":"Neuropsychol. Rev."},{"issue":"1\u20132","key":"10.1016\/j.jneuroim.2018.05.014_bb0155","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.jneuroim.2014.03.001","article-title":"Anti-MOG antibodies in adult patients with demyelinating disorders of the central nervous system","volume":"270","author":"Tanaka","year":"2014","journal-title":"J. Neuroimmunol."},{"issue":"1\u20133","key":"10.1016\/j.jneuroim.2018.05.014_bb0160","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1385\/IR:36:1:221","article-title":"Age-dependent alterations of the T cell repertoire and functional diversity of T cells of the aged","volume":"36","author":"Vallejo","year":"2006","journal-title":"Immunol. Res."},{"issue":"3","key":"10.1016\/j.jneuroim.2018.05.014_bb0165","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1111\/ene.12898","article-title":"Neuromyelitis optica spectrum disorders: comparison of clinical and magnetic resonance imaging characteristics of AQP4-IgG versus MOG-IgG seropositive cases in the Netherlands","volume":"23","author":"van Pelt","year":"2016","journal-title":"Eur. J. Neurol."},{"issue":"3","key":"10.1016\/j.jneuroim.2018.05.014_bb0170","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000089","article-title":"MOG cell-based assay detects non-MS patients with inflammatory neurologic disease","volume":"2","author":"Waters","year":"2015","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"16","key":"10.1016\/j.jneuroim.2018.05.014_bb0175","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1016\/S0264-410X(99)00497-1","article-title":"Changes in the B-cell repertoire with age","volume":"18","author":"Weksler","year":"2000","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.jneuroim.2018.05.014_bb0180","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.jneuroim.2018.05.014_bb0185","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000062","article-title":"Does MOG Ig-positive AQP4-seronegative opticospinal inflammatory disease justify a diagnosis of NMO spectrum disorder?","volume":"2","author":"Zamvil","year":"2015","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.jneuroim.2018.05.014_bb0190","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.jneuroim.2017.01.007","article-title":"MOG-antibody associated demyelinating disease of the CNS: a clinical and pathological study in Chinese Han patients","volume":"305","author":"Zhou","year":"2017","journal-title":"J. Neuroimmunol."}],"container-title":["Journal of Neuroimmunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165572818300638?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165572818300638?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T08:32:21Z","timestamp":1759048341000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165572818300638"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":37,"alternative-id":["S0165572818300638"],"URL":"https:\/\/doi.org\/10.1016\/j.jneuroim.2018.05.014","relation":{},"ISSN":["0165-5728"],"issn-type":[{"value":"0165-5728","type":"print"}],"subject":[],"published":{"date-parts":[[2018,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Different features between pediatric-onset and adult-onset patients who are seropositive for MOG-IgG: A multicenter study in South China","name":"articletitle","label":"Article Title"},{"value":"Journal of Neuroimmunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jneuroim.2018.05.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}